Synthetech, Inc. (NZYM) - 500 Beiträge pro Seite

[panik]

Profile:Synthetech, Inc. operates as a chemicals company primarily in organic synthesis, biocatalysis, and chiral technologies. Its products include amino acid derivatives, specialty amino acids, peptide fragments, and chiral intermediates. The company also manufactures products for use in cosmeceuticals. Its products are used in peptide, peptidomimetic small molecule, other drugs under development, or for the treatment of AIDS, cancer, cardiovascular, and other diseases. The company offers its products to pharmaceutical, drug synthesis, and cosmeceutical companies. In addition, it also offers its products to research institutions, universities, and drug discovery firms. The company markets its products primarily in the United States, Europe, and Japan. Synthetech was organized in 1981 and is headquartered in Albany, Oregon.

http://www.synthetech.com/

[panik]

NZYM (46c +15%): Synthetech CFO, Gary Weber, bought 10,800 shares at 41c today.

Synthetech (NZYM) develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, and proprietary custom chiral intermediates primarily for the pharmaceutical and cosmeceutical industries.

NYZM is a deep value proposition. The company trades at 58% of its tangible book value of 79.3c/share. As of June 30, NZYM had 26c/share of cash and marketable securities on its balance sheet.

Revenue is declining however. NZYM reported $1.19 million in Q2 sales vs. $2.74 million the year prior. Net loss more than doubled to (7c) from (3c).

The company cited risks from competition. According to its 10-Q filing, Synthetech "is at a competitive disadvantage compared to contract drug synthesis companies that can support further downstream production in accordance with the FDA’s current Good Manufacturing Practices (cGMP)." The firm also is "encountering competition from developing countries such as India and China."

[panik]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934


AUGUST 11, 2005
Date of Report
(Date of earliest event reported)


Synthetech, Inc.

(Exact name of registrant as specified in its charter)


Oregon 0-12992 84-0845771
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)


1290 Industrial Way, Albany, OR 97322
(Address of principal executive offices and zip code)

[phone]
(Registrant`s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))

<PAGE>

ITEM 7.01. REGULATION FD DISCLOSURE

In Synthetech`s SEC Report on Form 10-Q for the quarter ended June 30, 2005,
Synthetech stated:

"In spite of our recent results, Synthetech`s pipeline of clinical projects
remains robust, with about a dozen active projects in mid- to late-stage
clinical trials for which we are supplying key intermediates and many other
projects at earlier stages of the drug development cycle. We expect to be
named as an approved supplier of intermediates in three New Drug
Applications to be filed by our customers during fiscal 2006 following
completion of Phase 3 clinical trials currently in progress. Synthetech has
supported each of these projects for years as they have progressed through
the drug development cycle. Although we face a challenging environment in
the near-term, we believe that Synthetech`s pipeline of projects has the
potential to generate longer-term revenue significantly above amounts in
recent fiscal years."

The three drugs under development mentioned above relate to the treatment of
diabetes and cancer and to veterinary applications, respectively. Synthetech has
received another order relating to the diabetes drug project for delivery in
November 2005. The cancer drug is targeted at multiple indications, with two
indications in Phase 3 clinical trials and others in Phase 2 trials. The cancer
drug likely would be subject to fast-track approval by the U.S. Food and Drug
Administration, which would take at least six months following the New Drug
Application filing.

Management believes that, if the drugs receive regulatory approval and market
acceptance, the diabetes drug could result eventually in annual revenue to
Synthetech in the range of $3 to 10 million, and that all three drugs could
result eventually in annual revenue to Synthetech of approximately $15 million.
However, none of these drugs may be approved, and even though Synthetech expects
to be named as an approved supplier in the New Drug Applications, there is no
assurance with respect to the timing, volume, frequency or repetition of orders.

FORWARD LOOKING STATEMENTS

This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, including statements regarding future
results of operations or financial position, made in this Current Report are
forward looking. Words such as "anticipates," "believes," "expects," "future"
and "intends" and similar expressions may identify forward-looking statements.
In particular, forward-looking statements in this report include statements
regarding: our future operating results, including future revenue from existing
drug development projects; obtaining regulatory approval for new drugs and other
matters relating to drug development progress, including filings and filing
dates related to the approval process; and market acceptance of new drugs.
Forward-looking statements reflect management`s current expectations, plans or
projections and are inherently uncertain. Actual results could differ materially
from management`s expectations,

<PAGE>
plans or projections. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this report. The
risks and uncertainties that may cause actual results to vary materially from
any forward-looking statements include, but are not limited to, the following:
the uncertain market for new drugs or our products; potential loss of a
significant customer; potential termination or suspension by customers of
significant projects; our limited financial and other resources; production
factors; industry cost factors; competition; and government regulation.
Investors are urged to read our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the fiscal year ended
March 31, 2005, for a further description of risks and uncertainties related to
forward-looking statements made by us as well as to other aspects of our
business. Synthetech does not intend to release any revisions to these
forward-looking statements that may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.

<PAGE>


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Dated: August 12, 2005 Synthetech, Inc.


By: /s/ GARY A. WEBER
---------------------
Gary A. Weber
Chief Financial Officer
</TEXT>
</DOCUMENT>

[icemen]

+13%
kurzfristiges kursziel 1$

[juta]

[panik]

[icemen]

weiter geht es +13%

das ist erst der anfang!

[icemen]

wahnsinn keiner interesiert??????
Synthetech wird der hammer!!!!!

[Naposim]

Na dann erzähl mal warum das ein Hammer wird?
Bin seit heut morgen investiert!

[panik]

Synthetech`s Board of Directors Appoints New Chairman
Thursday August 25, 4:01 pm ET


ALBANY, Ore., Aug. 25 /PRNewswire-FirstCall/ -- Synthetech, Inc. (Nasdaq: NZYM - News) announced today that its Board of Directors has appointed Daniel T. Fagan as Chairman of the Board. Dr. Fagan, 53, has served as a Synthetech director since 2001 and he succeeds Paul C. Ahrens, who is a founder of Synthetech and will remain a director of the company.




Dr. Fagan is also the President and CEO and a director of PepTx, Inc., a start-up biopharmaceutical company that is developing peptide-based oncology therapeutics. Dr. Fagan`s previous experience includes serving as General Manager of Peptides for Mallinckrodt, Inc., a subsidiary of Tyco International, and as the President of Sigma Chemical, a subsidiary of Sigma Aldrich Corporation which manufactures fine chemicals. Dr. Fagan holds a Chemistry degree from Otterbein College and a Ph.D. in Chemistry from Case Western Reserve University.

"This is an exciting time to become more involved with Synthetech and I am pleased with the opportunity to succeed Paul as Chairman of the Board," said Dr. Fagan. "There is growing interest in synthetic peptides for therapeutic and other non-pharmaceutical applications and Synthetech is well positioned to benefit from this trend. Synthetech has developed an excellent track record with customers in its product and technology segments and I believe in, and look forward to helping to chart, Synthetech`s long-term future. I am eager to work with management and my fellow Board members to meet the short-term challenges now facing the company."

"Dan has been a tremendous resource to Synthetech with his vision and industry knowledge," said Mr. Ahrens. "Dan`s oversight and guidance will be invaluable in helping Synthetech implement its growth and diversification strategies. We look forward to working with Dan in this new role."

In addition to continuing to serve as a director, it is anticipated that Mr. Ahrens will continue to provide research and market development consulting services to Synthetech.

About Synthetech

Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, and proprietary custom chiral intermediates primarily for the pharmaceutical and cosmeceutical industries. Synthetech`s products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer`s clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases, and in cosmeceuticals.

Synthetech`s common stock is listed on the Nasdaq SmallCap Market where it trades under the symbol "NZYM."


MORE INFORMATION: Web site: www.synthetech.com
E-mail: [e-mail]

CONTACT: M. "Sreeni" Sreenivasan, President & CEO
Gary Weber, CFO
PO Box 646
Albany, Oregon 97321
541-967-6575




--------------------------------------------------------------------------------
Source: Synthetech, Inc.